Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene - Wikidata - awgldk - TriplyDB

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

http://www.wikidata.org/entity/Q34593929

about

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms Molecular biology of lung cancer: clinical implications Clinical use of crizotinib for the treatment of non-small cell lung cancer The role of the ALK receptor in cancer biology Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options ALK and ROS1 as a joint target for the treatment of lung cancer: a review Emerging importance of ALK in neuroblastoma Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice ALK and NSCLC: Targeted therapy with ALK inhibitors From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Molecular pathways and therapeutic targets in lung cancer Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.SHP2E76K mutant promotes lung tumorigenesis in transgenic mice Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer The tandem affinity purification technology: an overview.The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.ALK in lung cancer: past, present, and future.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features.New strategies for treatment of ALK-rearranged non-small cell lung cancers.Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer.Genetic and biochemical alterations in non-small cell lung cancer.

P2860

Q21129306-B942C1EA-7631-4D07-B8F5-DB6F9362D245 Q24294276-584C72D0-92E5-448F-AB01-6B84C7F7B198 Q24339394-69DE8497-81B1-420B-ADAE-325DA828A3AC Q24610335-C0E0626B-D2A1-4773-8B62-F50F16538048 Q24630466-4A3BCAEA-A752-47FC-9102-0078AC353B6F Q26738384-384BD95A-F954-40F4-BBE3-4FD30204A8AD Q26745427-DFF20A54-D48F-4339-B4FA-6FE25252C857 Q26766039-2FB63C76-A7AD-4610-8EA2-0781871F4DA1 Q26820845-BD143E72-1953-43F3-8AF9-38BC3F16EB47 Q26851392-62C60E02-1474-44E6-92E1-9FF6DAEE226A Q26858819-5CB65581-F9FB-47B8-B24C-33ECA4BFA3E6 Q27851710-D09D8F22-19F1-4D95-9C0E-04206AC5894D Q28071903-B3CB6A0B-AB83-4356-BCD1-02D178C0FE4E Q28393324-025BBE71-5106-4ACE-B008-21A43FD741B6 Q28533949-DB4B36B5-EA3B-4612-898F-A44609921471 Q31167585-3C55F07E-7A20-44D6-9310-5D0C622648B2 Q33688872-F20324A3-329A-4F77-9A32-7FE585EFDAB8 Q33860904-CA8B9B73-E89D-4103-9888-3CA6464FD168 Q33897022-A9F759A4-7AA2-4681-A3AB-C45C56F3B0C8 Q34009953-7D8A3984-BFA6-4F16-B1F5-8622760E73D5 Q34055939-DBCA656E-B9F3-4C16-9D60-FD3A8C198254 Q34135320-DEE430EF-7A1B-458E-8E5C-70DDB81AFA63 Q34156513-9CE15B18-6291-41AE-8E05-DEFEF21100C5 Q34172439-59F2DC63-8648-4B06-AEB5-3E896FE4EB09 Q34297784-A904E5F8-ADB0-4870-8471-2DF09338B5D3 Q34402260-4FC66FB0-756B-4BE5-AD9F-8B15C04CE1F0 Q34558207-0D2E536A-E576-4EE2-8353-556C818173AF Q34564071-A459E6BC-A670-4467-AB43-3032DB4EECDC Q34619336-F94B7796-D0D7-4491-B0CE-BD227C3A988B Q34633121-09151DC3-7AEA-4E4A-B2B7-5EBE6B677EFB Q34938204-8EAF7D28-77BA-4F4C-B10A-E4D12B0FC882 Q34970672-D086E5DF-8C1A-4F02-8DA2-43E60783DFE0 Q35011473-E934A560-48F2-4F34-AE3F-F3CF1743D23C Q35112834-6333C135-EE40-4E74-8224-7CEE4AE066BB Q35159149-68B664A6-BB30-493F-AC3C-2F4FC7E01BC1 Q35720969-09202469-56A1-4A02-AAA4-B553A86B2D1E Q35741716-01DD48AA-7B77-44B1-8C43-40574132600C Q36006242-10E4B527-0F78-489D-BED3-BA73B7176E85 Q36173303-7C149F75-18A4-4CC0-B640-E083CFCBBC3A Q36184584-21623C3C-79AB-4A4B-A5C9-7FFCB6F17C6D

P2860

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

http://www.wikidata.org/entity/Q34593929

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@ast

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@en

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@nl

type

label

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@ast

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@en

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@nl

prefLabel

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@ast

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@en

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@nl

P1433

Q34593929-4A482474-0125-474D-87CC-255EB797200B

P1476

Q34593929-095A6AB1-62A8-4A85-90B3-ACE64501A5E1

P2093

Q34593929-03ACB8AC-9278-4005-B950-12EF6A5354C1

Q34593929-078AF65E-00E8-433B-A7F0-AD981B1B82E5

Q34593929-30AA0931-85CF-4C08-BF80-79E4116E39E1

Q34593929-479A4D4A-5F84-422E-BE51-83392C55C223

Q34593929-6A3F2CBB-F45D-4997-9198-423D7AE3FCFC

Q34593929-70D1EF58-495E-43C2-AEB6-E03FD78A14B5

Q34593929-7130FF9C-9326-4DD5-86C8-AB41335EBA0E

Q34593929-9C6DF540-9A35-4BA9-9748-1EE10FDA50A6

Q34593929-A70C63D8-1FE9-4463-B778-590EEF3D9CC0

Q34593929-AC57C5C9-DD13-4FAE-B5F3-7F7D3F61BE84

P2860

Q34593929-0F5A14FF-C9BF-4285-8EA3-92A4B90EA8FB

Q34593929-12236CDD-E798-4096-8AAF-226167F5C3E8

Q34593929-1936127B-07C2-4F83-8369-8913699F38F1

Q34593929-2061A64F-7D45-4518-82D9-D43D4E95426F

Q34593929-21DF118C-EB60-44A8-BF0A-0161F7402EDB

Q34593929-2222079E-77BD-47F0-9A90-E5E879406A65

Q34593929-236854F8-6C13-4F7A-915B-714065318AA4

Q34593929-25A934BF-6400-4603-B1DF-9ED1E3F44329

Q34593929-366ECACC-0687-49B7-AF28-B5BB38328F60

Q34593929-37CEB620-65BE-4850-86CC-8B10D220FC2D

P304

Q34593929-1CCD7B05-FAE0-4CC2-A8E1-3D7939A004BB

P31

Q34593929-64DDFC1B-EFD4-4750-BD8C-F6651380E56C

P356

Q34593929-3CB43747-56FF-4E35-9071-50A9579D0535

P407

Q34593929-EFCF1CF3-B657-40FB-A748-BC1EDCEF87CB

P433

Q34593929-1ACA5868-A4D6-457D-BC70-E0247684874F

P478

Q34593929-CEA7F989-48BC-477D-9802-E2BF1B0C1B4B

P50

Q34593929-087A09D3-68A6-4B04-A389-B87CBDA95C64

Q34593929-192F9E48-A519-46AA-8678-1863472EBE85

Q34593929-227C38B9-F9AE-4FB6-A205-BDD912D469F3

Q34593929-45D7D976-9FCF-46A7-9FE7-C60BFEA5B79D

Q34593929-5798A92E-B242-44B6-8AE3-7288AA9A6FE5

Q34593929-A59F5A0A-E74B-4467-8B14-F3F2220E3E87

P577

Q34593929-F6191AB0-1B34-429A-AB32-D11A75F1A4B4

P698

Q34593929-3BF9D2A0-2067-4AC2-BEBC-CD4DED985299

P921

Q34593929-1124802E-135D-41C7-8380-9F62AE94FFB3

P932

Q34593929-8B9EFEB0-BF51-42AA-811B-9F5808168F4F

P356

0008-5472.CAN-10-1671

P1433

Cancer Research

P1476

Inhibition of ALK, PI3K/MEK, a ...... ed by EML4-ALK fusion oncogene

@en

P2093

Christa Borgman

http://www.w3.org/2001/XMLSchema#string

Chunxiao Xu

http://www.w3.org/2001/XMLSchema#string

Danan Li

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Guillaume O Adelmant

http://www.w3.org/2001/XMLSchema#string

Hyeong Ryul Kim

http://www.w3.org/2001/XMLSchema#string

Hyun Joo Lee

http://www.w3.org/2001/XMLSchema#string

Jarrod A Marto

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Pasi A Jänne

http://www.w3.org/2001/XMLSchema#string

P2860

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

Anaplastic lymphoma kinase: signalling in development and disease

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

9827-9836

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-1671

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Julian Carretero

Marzia Capelletti

P577

2010-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20952506

http://www.w3.org/2001/XMLSchema#string

P921

P932

3043107

http://www.w3.org/2001/XMLSchema#string